Otorrhoea is a marker for symptomatic disease in HIV-infected children

被引:0
|
作者
Karpakis, J. [1 ,2 ]
Rabie, H. [1 ,2 ]
Howard, J. [1 ,2 ]
van Rensburg, A. Janse [1 ,2 ]
Cotton, M. F. [1 ,2 ]
机构
[1] Typerberg Childerns Hosp, Dept Paediat & Child Hlth, Childrens Infect Dis Clin Res Unit, W Cape, South Africa
[2] Univ Stellenbosch, ZA-7600 W Cape, South Africa
来源
SAMJ SOUTH AFRICAN MEDICAL JOURNAL | 2007年 / 97卷 / 12期
关键词
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background. Chronic otorrhoea occurs commonly in HIV-infected children. However, there are few data on incidence and severity. Objective. To document the prevalence of otorrhoea in the clinic attendees. Methods. A retrospective chart review was done of all HIV-I infected children seen at the Family Clinic for HIV from 1 February 1997 to 31 December 2001, a period preceding widespread availability of antiretrovirals. Otorrhoea was classified into two groups, viz. group 1 (mild): an episode lasting less than 1 month, and group 2 (severe): an episode lasting more than 1 month or more than 1 episode of otorrhoea. The clinical and immune stages of the children were noted. Results. Of 326 children seen during the study period, 104 (32%) had otorrhoea. Forty-five (13.8%) had mild and 59 (18.1%,) severe otorrhoea. Two hundred and eighty-eight (88.6'%) had either Centers for Disease Control stage B or C disease. The median CD4 percentage in children with otorrhoea was 17.5% (8.3 - 23%) versus 21% (14 - 28%) in those without otorrhoea (p=0.004). The odds ratio (OR) of children in stage B or C not having severe otorrhoea was 0.1 (0.01 - 0.72, p = 0.013). The OR for immune class 2 or 3 without severe otorrhoea was 0.39(0.18 - 0.85, p=0.021). Conclusions. Otorrhoea contributes to the morbidity of HIV infection in children. It is a marker for symptomatic disease and CD4 depletion and should be included in clinical classifications.
引用
收藏
页码:1292 / 1294
页数:3
相关论文
共 50 条
  • [1] Virus load as a marker of disease progression in HIV-infected children
    Tetali, S
    Abrams, E
    Bakshi, S
    Paul, M
    Oyaizu, N
    Pahwa, S
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 1996, 12 (08) : 669 - 675
  • [2] Cryptococcal Disease in HIV-Infected Children
    Carol Kao
    David L. Goldman
    Current Infectious Disease Reports, 2016, 18
  • [3] Cryptococcal Disease in HIV-Infected Children
    Kao, Carol
    Goldman, David L.
    CURRENT INFECTIOUS DISEASE REPORTS, 2016, 18 (09)
  • [4] ATOPIC DISEASE IN HIV-INFECTED CHILDREN
    SCHUVAL, S
    BONAGURA, V
    SAPERSTEIN, J
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1995, 95 (01) : 247 - 247
  • [5] The pathogenesis of heart disease in HIV-infected children
    Jiminez, S
    Kearney, DL
    Stetson, S
    Torre-Amione, G
    Shearer, WT
    Towbin, JA
    Bowles, NE
    PEDIATRIC RESEARCH, 2002, 51 (04) : 33A - 33A
  • [6] PULMONARY-DISEASE IN HIV-INFECTED CHILDREN
    KATTAN, M
    SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 1995, 16 (03) : 231 - 239
  • [7] Pulmonary disease in HIV-infected African children
    Graham, SM
    Coulter, JBS
    Gilks, CF
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2001, 5 (01) : 12 - 23
  • [8] HIV-INFECTED CHILDREN
    不详
    LANCET, 1992, 339 (8807): : 1474 - 1475
  • [9] Zidovudine, didanosine, or both as the initial treatment for symptomatic HIV-infected children
    Englund, JA
    Baker, CJ
    Raskino, C
    McKinney, RE
    Petrie, B
    Fowler, MG
    Pearson, D
    Gershon, A
    McSherry, GD
    Abrams, EJ
    Schliozberg, J
    Sullivan, JL
    NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (24): : 1704 - 1712
  • [10] Complicated and Protracted Cryptococcal Disease in HIV-infected Children
    Hassan, Haseena
    Cotton, Mark F.
    Rabie, Helena
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2015, 34 (01) : 62 - 65